Pack-Years of Cigarette Smoking as a Prognostic Factor in Patients With Stage IIIB/IV Nonsmall Cell Lung Cancer

被引:108
作者
Janjigian, Yelena Y. [1 ]
McDonnell, Kevin [1 ]
Kris, Mark G. [1 ]
Shen, Ronglai [2 ]
Sima, Camelia S. [2 ]
Bach, Peter B. [2 ]
Rizvi, Naiyer A. [1 ]
Riely, Gregory J. [1 ]
机构
[1] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Thorac Oncol Serv,Div Solid Tumor Oncol,Dept Med, New York, NY 10021 USA
[2] Cornell Univ, Weill Med Coll, Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA
基金
美国国家卫生研究院;
关键词
nonsmall cell lung cancer; cigarettes; smoking history; pack-years; survival; prognostic factor; NEVER-SMOKERS; PULMONARY ADENOCARCINOMA; CLINICAL CHARACTERISTICS; SURVIVAL; CHEMOTHERAPY; MUTATIONS; GEFITINIB; HISTOLOGY; HISTORY; ENTITY;
D O I
10.1002/cncr.24813
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: This study was undertaken to characterize the relation between the survival of patients with stage IIIB/IV nonsmall cell lung cancer (NSCLC) and pack-years of cigarette smoking (graded according to the American Joint Committee on Cancer staging system). METHODS: Data were analyzed from patients with stage IIIB/IV NSCLC who had completed a prospective smoking questionnaire. The impact of pack-years of cigarette smoking, age, sex, Karnofsky performance status (KPS), and the presence of weight loss >5% was evaluated on overall survival using univariate and multivariate analyses. RESULTS: Smoking history and clinical data were available for 2010 patients with stage IIIB/IV NSCLC (1004 women and 1006 men). Approximately 70% of patients (1409 patients) had smoked >15 pack-years, 13% (270) were former and current smokers who had smoked <= 15 pack-years, and 16% (331) were never-smokers (<100 lifetime cigarettes). Never-smokers had a longer median survival compared with former or current smokers (17.8 months vs 11.3 months; log-rank P < .001). Among smokers, patients with a <= 15 pack-year history of smoking had a longer median survival than patients who had smoked >15 pack-years (14.6 months vs 10.8 months; log-rank P = .03). As the number of pack-years increased, the median overall survival decreased (log-rank P < .001). Multivariate analysis indicated that a history of smoking was an independent prognostic factor (hazard ratio, 1.36; P <.001). CONCLUSIONS: More cigarette smoking, measured in pack-years, was associated with decreased survival after a diagnosis of stage IIIB/IV NSCLC. Trials assessing survival in patients with stage IIIB/IV NSCLC should report a detailed cigarette smoking history for all patients. Cancer 2010;116:670-5.(C) 2009 American Cancer Society.
引用
收藏
页码:670 / 675
页数:6
相关论文
共 29 条
[1]  
[Anonymous], 2005, LUNG CANC
[2]  
[Anonymous], J CLIN ONCOL 1, DOI DOI 10.1200/jco.2006.24.18_suppl.7020
[3]   Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer [J].
Bryant, Ayesha ;
Cerfolio, Robert James .
CHEST, 2007, 132 (01) :185-192
[4]   Duration of smoking abstinence as a predictor for non-small-cell lung cancer survival in women [J].
Ebbert, JO ;
Williams, BA ;
Sun, Z ;
Aubry, MC ;
Wampfler, JA ;
Garces, YI ;
Meyer, RL ;
Yang, P .
LUNG CANCER, 2005, 47 (02) :165-172
[5]  
EBERHARD DA, 2005, J CLIN ONCOL, V2, P857
[6]   Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas [J].
Fujisawa, T ;
Iizasa, T ;
Saitoh, Y ;
Sekine, Y ;
Motohashi, S ;
Yasukawa, T ;
Shibuya, K ;
Hiroshima, K ;
Ohwada, H .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2086-2091
[7]   Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma [J].
Marks, Jenifer L. ;
Broderick, Stephen ;
Zhou, Qin ;
Chitale, Dhananjay ;
Li, Allan R. ;
Zakowski, Maureen F. ;
Kris, Mark G. ;
Rusch, Valerie W. ;
Azzoli, Christopher G. ;
Seshan, Venkatraman E. ;
Ladanyi, Marc ;
Pao, William .
JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) :111-116
[8]   Clinical factors and prognosis in non-small cell lung cancer [J].
Martins, SJ ;
Pereira, JR .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1999, 22 (05) :453-457
[9]   Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer [J].
Miller, VA ;
Kris, WG ;
Shah, N ;
Patel, J ;
Azzoli, C ;
Gomez, J ;
Krug, LM ;
Pao, W ;
Rizvi, N ;
Pizzo, B ;
Tyson, L ;
Venkatraman, E ;
Ben-Porar, L ;
Memoli, N ;
Zakowski, M ;
Rusch, V ;
Heelan, RT .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (06) :1103-1109
[10]   Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma. [J].
Mok, Tony S. ;
Wu, Yi-Long ;
Thongprasert, Sumitra ;
Yang, Chih-Hsin ;
Chu, Da-Tong ;
Saijo, Nagahiro ;
Sunpaweravong, Patrapim ;
Han, Baohui ;
Margono, Benjamin ;
Ichinose, Yukito ;
Nishiwaki, Yutaka ;
Ohe, Yuichiro ;
Yang, Jin-Ji ;
Chewaskulyong, Busyamas ;
Jiang, Haiyi ;
Duffield, Emma L. ;
Watkins, Claire L. ;
Armour, Alison A. ;
Fukuoka, Masahiro .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (10) :947-957